pioglitazone has been researched along with Ureteral Obstruction in 3 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Ureteral Obstruction: Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the additive protective effects of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone (Pio) and the angiotensin II receptor blocker candesartan (Cand) in a murine model of renal fibrosis: mice with unilateral ureteral obstruction (UUO)." | 7.76 | Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. ( Higashi, K; Hyodo, T; Kumagai, H; Kushiyama, T; Miura, S; Oda, T; Sakurai, Y; Suzuki, S; Yamada, M, 2010) |
| "Pioglitazone has been demonstrated to exert anti-fibrotic and renoprotective effects." | 5.51 | Pioglitazone attenuates kidney fibrosis via miR-21-5p modulation. ( Chen, Y; Qu, W; Song, X; Sun, D; Sun, L; Xu, T; Yao, L; Yuan, Q, 2019) |
| "To examine the additive protective effects of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone (Pio) and the angiotensin II receptor blocker candesartan (Cand) in a murine model of renal fibrosis: mice with unilateral ureteral obstruction (UUO)." | 3.76 | Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. ( Higashi, K; Hyodo, T; Kumagai, H; Kushiyama, T; Miura, S; Oda, T; Sakurai, Y; Suzuki, S; Yamada, M, 2010) |
| "Pioglitazone has been demonstrated to exert anti-fibrotic and renoprotective effects." | 1.51 | Pioglitazone attenuates kidney fibrosis via miR-21-5p modulation. ( Chen, Y; Qu, W; Song, X; Sun, D; Sun, L; Xu, T; Yao, L; Yuan, Q, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, L | 1 |
| Xu, T | 1 |
| Chen, Y | 1 |
| Qu, W | 1 |
| Sun, D | 1 |
| Song, X | 1 |
| Yuan, Q | 1 |
| Yao, L | 1 |
| Han, JY | 1 |
| Kim, YJ | 1 |
| Kim, L | 1 |
| Choi, SJ | 1 |
| Park, IS | 1 |
| Kim, JM | 1 |
| Chu, YC | 1 |
| Cha, DR | 1 |
| Higashi, K | 1 |
| Oda, T | 1 |
| Kushiyama, T | 1 |
| Hyodo, T | 1 |
| Yamada, M | 1 |
| Suzuki, S | 1 |
| Sakurai, Y | 1 |
| Miura, S | 1 |
| Kumagai, H | 1 |
3 other studies available for pioglitazone and Ureteral Obstruction
| Article | Year |
|---|---|
Pioglitazone attenuates kidney fibrosis via miR-21-5p modulation.
Topics: Animals; Cell Line; Fibrosis; HEK293 Cells; Humans; Kidney; Kidney Diseases; Male; Mice; Mice, Inbre | 2019 |
PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis.
Topics: Angiotensin Receptor Antagonists; Animals; Antigens, Differentiation; Disease Models, Animal; Fibros | 2010 |
Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biomarkers; Biphenyl | 2010 |